Cypress Acquires Personalized Medicine Technology from Cellatope | GenomeWeb

NEW YORK (GenomeWeb News) – Cypress Bioscience has acquired Cellatope's technology platform for diagnosing and monitoring autoimmune disorders, such as lupus, for up to $5 million.

San Diego-based Cypress said that the technology platform uses cell-bound complement activation products for diagnosis and monitoring of response to treatment. It was developed by researchers at the Lupus center for Excellence at the University of Pittsburgh to evaluate cell-bound fragments of activated complement proteins and their utility in diagnosis and monitoring of lupus patients.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.